ES IST RUHIG GEWORDN GIEBT ES NOCH FREUNDE - 500 Beiträge pro Seite

[Wuscher]

MOIN MOIN
CURIS
der überflieger
völlig unter bewertet
RIESEN peiplein
nur mal nachprüfen
VERGESSEN ????????

[Mr.Keating]

@ Wuscher

Na klar. Ich bin der größte Freund
und werde es bestimmt noch 1-2 Jährchen
bleiben.
Wie du es schon gesagt hast.
Curis ist top, bleibt top und wird
es auch bald vom Kurs her sein. ( 60Euro ??? )
Curis gibt mir die Chance mal von Anfang an dabei
zu sein wenn ein riese geboren wird.
Denn sie hat ja wohl das gleiche Potenzial wie
eine Medarex oder Vertex.
Vorallem der Fakt, dass Curis auch den Kosmetischenmarkt
revolutionieren wird und sie dort eine Vorreiterstellung haben,
sollte sich auch bald in den Kursen niederschlagen.
Ich denke, dass es wichtig ist, dass Curis das erste
von den drei Phase III Produkten rausbringt, denn dann
wird es kein halten mehr geben und es werden sich die institutionellen
Investoren um Curis reißen.

Also viel Spass noch.

P.S. Stelle nachher mal eine US Einschätzung rein.

MfG Mr.Keating

[Wuscher]

moin moin
ist nur schade das so wenige
das potential dieser aktie erkennen
denke aber auch
das wierd sich bald ändern
mfg

[wert111]

Brauche Depot bewertung

Vertex 20+
Commerce One 16+
Ariba 9+
Check point 22+
Affymetrix 9+
DAC UI 21+

[pteppic]

hi @all

Auf der curis hp steht unter news etwas von quartalszahlenveröffentlichung am 26.10.00.
Hab ich das richtig verstanden ?Könnte mal jemand unter www.curis.com nachsehen was dort steht?(mein englisch ist echt mies)
Hat jemand außerdem ein paar news zu unserem baby?

Gruß PTEPPIC

[Wuscher]

moin moin
die machen es einem wierklich
nicht leicht!!!
vieleicht heute mal
mfg

[gholzbauer]

Hedgehog Protein Under Development by Curis Restores Complete Nerve Function in Pre-Clinical Models of Diabetic Neuropathy
CAMBRIDGE, Mass., Nov 3, 2000 (BW HealthWire) -- Findings presented yesterday at the Fifth Annual Diabetic Neuropathy Satellite Meeting of the Society for Diabetic Neuropathy showed that treatment with the Sonic Hedgehog protein, under development by Curis, Inc. (NASDAQ: CRIS chart, msgs), restored nerve function to normal in pre-clinical models of diabetic neuropathy.

Data from a study conducted by Dr. David Tomlinson of the University of Manchester showed complete restoration of both sensory and motor nerve function in pre-clinical models after that function was impaired. Five weeks after treatment on these models was begun, nerve conduction velocity measurements showed that sensory and motor function returned to pre-diabetic levels.

"These findings are an important part of the pre-IND program for a Hedgehog-based treatment for diabetic neuropathy at Curis," said Doros Platika, M.D., president and chief executive officer of Curis. "The repair and restoration of normal function in nerves that have been compromised by diabetes, as shown in this study, represents a key objective of the company`s efforts in developmental biology, and we are moving forward aggressively to move such a therapy into human clinical testing."

Of the estimated 15 million people with diabetes in the U.S., approximately six million patients have diabetic neuropathy. The market for treatments of this condition is estimated to be $1.5 billion. Additional neurological diseases that may benefit from a Hedgehog-based therapy include multiple sclerosis, chemotherapy-induced neuropathy, Alzheimer`s disease, and amyotrophic lateral sclerosis.

The family of Hedgehog proteins and their role in the development of neuronal cells and tissues are a key focus of ongoing research and development at Curis. The development of innovative therapies by Curis to treat a variety of disorders, including diabetes, is focused upon recreating the conditions and redirecting key inducing molecules such as those involved in the Hedgehog pathway that control the normal growth and restore the function of tissues.

[gholzbauer]

Analysis: Have genome, will travel... how?
NEW YORK, Oct. 30 (UPI) -- Now that a draft of the human genome is on the table, the question is what to do with it.

Organizing the tome of genetic information will likely fall to the pharmaceutical industry, given the competitive motivation to develop new drugs that are simultaneously more potent and have fewer side effects. Knowing targets down to their very nucleotides -- the building blocks of DNA -- is a powerful tool. "1/8Yet3/8 I am very skeptical that this 1/8information transfer3/8 will happen within the classical pharmaceutical industry," said Dr. Jurgen Drews, who served at Roche as president of global research for 12 years. "The task at hand will be increasingly done by small biotech companies, and the biotechnology industry in general." Drews and other experts at the interface of genomics and information technology met at a two-day conference, sponsored by Scientific American, last week in New York. The avalanche of data has come not only from the Human Genome Project, but from the last eight years in general, said Drews, International Biomedicine Management Partners chairman at the Biosilico meeting. He asserts such information will result in the development of new drugs only if both forces team up to understand better the relationship between drug molecules and targets. That endeavor, however, is more difficult than scientists had believed in the mid-1990s, he added. While Drews estimates that the number of new drug targets has increased from 500 a decade ago to 3,000 to 10,000 today, he told conference attendees the pharmaceutical industry`s ability to discover new drugs from those targets has not really improved in this period of time. At the same time, however, new companies presented technologies focused on combining biotechnology with bioinformatics. Among them: * Entelos of Menlo Park, Calif., has designed computer-based models of asthma, diabetes, and obesity, which it offers on a subscription-basis. It is working with AstraZeneca, Bayer, Johnson & Johnson, Aventis and Proctor & Gamble with its computer-simulation of these complex diseases, said CEO Samuel Holtzman. Proctor & Gamble is developing an appetite-suppressant with Entelos` technology that is about to enter the clinic for human testing. The biotech company`s models help predict complex activities such as energy expenditure, brain signaling, fat storage and insulin management. It also helps predict how patients will react given various drug doses, taking into consideration a wide degree of patient variability.

"We can run a Phase III trial before a company does, and help them design a better trial for use in humans," said Holtzman. "We can also see where a trial will fail before it enters the clinic, and thereby help a company avoid the expense of actually failing in the clinic." Entelos has also helped companies determine whether a drug might be used ways other than those for which it had been developed, thereby expanding a drug`s use. Such "virtual" testing can reduce time and cost of clinical trials, and help determine which patients are most likely to respond to a particular drug. * GeneLogic`s databases include profiles of normal and diseased tissue, said Dr. Douglas Dolginow, senior vice president for pharmacogenomics. The company makes its databases, GeneExpress, ToxExpress and PharmExpress, available to drug companies for a licensing fee.

"Our databases can answer the question, `Why is a heart cell different from a kidney cell?,`" Dolginow said. "What distinguishes cells from the brain`s frontal cortex from those affected by Alzheimer`s disease?" ..As important is the use of GeneLogic`s databases to answer questions concerning the best treatment for different types of cancer -- which is the safest drug for a particular person, and which second-line therapy is most likely to be effective -- said Dolginow. * Physiome Sciences, led by CEO, chairman and founder Jeremy Levin, is developing software technology tools to predict biological models "for a smarter way of selecting drug candidates," Levin said. Computer-based models assembled by the Princeton, N.J.-based company so far include bladder, lung and heart. They are designed to help bench scientists decide where to focus their efforts, explained Levin. * Curis Inc. president and CEO Doros Platika said his recently merged company aims to change the way degenerative disease, cancer and other problems associated with loss of function are treated in this "post-genomics age." Curis, born of three Cambridge, Mass. biotech companies, is combining developmental biology, bioinformatics, genomics, and tissue engineering to track down the molecular basis of degenerative disease and injury, said Platika. He added the company has seven products in the clinic or under regulatory review that collectively are worth $7 billion, and a total of 15 in development over a four-year period. "By combining synergistic technologies, we are turning gene sequences into products that include small molecules, cells and growth factors," Platika said. Curis products include drugs and devices for non-union fractures, periodontal disease, spinal fusion, and basal cell carcinoma. * Another company focusing on moving genes toward drugs for regenerative medicine is Human Genome Sciences in Rockville, Md. A pioneer in gene discovery, the company made an early investment in genomics together with pharmaceutical giant SmithKline Beecham.

"We are focusing on identifying therapeutic proteins," said vice president and chief information officer Michael Fannon. To facilitate this discovery, HGS emphasizes its bioinformatics platform. Fannon said HGS is taking the public GenBank genes and searching against its own proprietary genes for receptors and secreted molecules.

(c) 2000 UPI All rights reserved.

[1048]

Hallo erst ma !!!!!
Könnte mir einer vieleicht etwas über die news von Curis sagen,habs
nicht so mit dem English.
Wenn einer news zu op-1 hat oder etwas intresantes über unsere Bioperle immer herdamit. Danke!!

Ihr leidet nicht allein!!!

[CaptainChaos]

Wenn meine Englisch - Sprachkentnisse mich nicht ganz im Stich gelassen haben, arbeitet CURIS auch erfolgreich an einem Protein, das Diabetes - geschädigte Nerven heilen/wiederherstellen kann.

Hedgehog Protein Under Development by Curis Restores Complete Nerve Function in Pre-Clinical Models of Diabetic Neuropathy

Business Wire
November 3, 2000 9:08am
CAMBRIDGE, Mass., Nov 3, 2000 (BW HealthWire) -- Findings presented yesterday at the Fifth Annual Diabetic Neuropathy Satellite Meeting of the Society for Diabetic Neuropathy showed that treatment with the Sonic Hedgehog protein, under development by Curis, Inc. (NASDAQ:CRIS), restored nerve function to normal in pre-clinical models of diabetic neuropathy.

Data from a study conducted by Dr. David Tomlinson of the University of Manchester showed complete restoration of both sensory and motor nerve function in pre-clinical models after that function was impaired. Five weeks after treatment on these models was begun, nerve conduction velocity measurements showed that sensory and motor function returned to pre-diabetic levels.

"These findings are an important part of the pre-IND program for a Hedgehog-based treatment for diabetic neuropathy at Curis," said Doros Platika, M.D., president and chief executive officer of Curis. "The repair and restoration of normal function in nerves that have been compromised by diabetes, as shown in this study, represents a key objective of the company`s efforts in developmental biology, and we are moving forward aggressively to move such a therapy into human clinical testing."

Of the estimated 15 million people with diabetes in the U.S., approximately six million patients have diabetic neuropathy. The market for treatments of this condition is estimated to be $1.5 billion. Additional neurological diseases that may benefit from a Hedgehog-based therapy include multiple sclerosis, chemotherapy-induced neuropathy, Alzheimer`s disease, and amyotrophic lateral sclerosis.

The family of Hedgehog proteins and their role in the development of neuronal cells and tissues are a key focus of ongoing research and development at Curis. The development of innovative therapies by Curis to treat a variety of disorders, including diabetes, is focused upon recreating the conditions and redirecting key inducing molecules such as those involved in the Hedgehog pathway that control the normal growth and restore the function of tissues.

Curis, Inc. is developing products based on technologies in the emerging field of regenerative medicine. The Company is combining insights gained through the study of developmental biology with high-throughput screening capabilities, proteins, cells and biocompatible materials to facilitate the development of new regenerative medicine therapies. For more information, please visit the Curis web site at HTTP://WWW.CURIS.COM.

THE statements in this news release that are not historical facts are forward-looking statements that involve risks and uncertainties including, without limitation, risks associated with the inherent uncertainty of pharmaceutical research, product development, regulatory approval and commercialization, the impact of competitive products, patents, patent litigation, product liability, third party reimbursement, and other risks and uncertainties associated with the biotechnology industry and mergers generally. For additional factors that could cause actual results to differ materially, please refer to the risk factors section of the Curis joint proxy statement/prospectus filed with the Securities and Exchange Commission on June 19, 2000.



CONTACT: for Curis, Inc.:
William B. Boni, [phone], ext. 6506
Cynthia Clayton, [phone], ext. 6641
or
for Noonan / Russo Communications:
Anthony Russo, [phone], ext. 202
Renee Connolly, [phone], ext.227

URL: HTTP://WWW.BUSINESSWIRE.COM
TODAY`S News On The Net - Business Wire`s full file on the Internet
with Hyperlinks to your home page.

Copyright (C) 2000 Business Wire. All rights reserved.
KEYWORD: MASSACHUSETTS INDUSTRY KEYWORD: BIOTECHNOLOGY MEDICAL

[Dago_IV]

Curis wird kommen das steht so fest wie das Amen in der Kirche,allein für das Diabetes-Medikament ist ein marktvolumen von 1,5Mrd.dollar da
für alle die nerven behalten gute Geschäfte rechne gerade mal 1470 mal
60 dollar guter schnitt wenns klappt.

[rütze]

fand damals die creative biomolecules auch schon nicht schlecht.
hab mal 100% mitgenommen.

[zockingmike]

das wird der durchbruch !!!

[Wuscher]

moin moin
hört sich wierklich richtig gut an
glaube auch das es jetzt gen norden geht